抑制MAPK通路改善了心力衰竭,由于盐敏感性高血压引起的射分数被保存
Shicheng Li1, Ying Shi1, Shanshan Yuan2
1Department of Cardiology, The People's Hospital of Guangxi Zhuang Autonomous Region; Institute of Cardiovascular Sciences, Guangxi Academy of Medical Sciences, Nanning 530021, China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|December 6, 2023
概括
一种MAPK抑制剂Doramapimod在治疗盐敏感高血压引起的心脏衰竭中显示出有前途. 这项研究成功地模拟了小鼠的HFpEF,并证明了Doramapimodod.
科学领域:
- 心血管生理学心血管生理学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭占心力衰竭病例的近50%.
- 高血压是HFpEF的一个重要因素.
- 需要进一步阐明MAPK信号通路在盐敏感高血压的次要HFpEF中的作用.
研究的目的:
- 建立和验证由盐敏感高血压引起的HFpEF的小鼠模型.
- 在这个HFpEF模型中研究MAPK抑制剂多拉玛皮莫德的治疗潜力.
- 在体外探索高盐度对肌体细胞的影响.
主要方法:
- 建立一个脱氧皮质乙酸盐 (DOCA-盐) 诱导的高血压小鼠模型.
- 评估心脏功能通过心脏回声学,血压监测,跑步测试和组织学分析.
- RNA测序 (RNA-seq) 用于分析基因表达,特别是MAPK信号通路,以及定量实时PCR (qRTPCR) 用于验证.
主要成果:
- DOCA-盐模型成功复制了HFpEF,其特点是左心室喷射分数 (LVEF) 超过50%.
- 在HFpEF模型中观察到MAPK信号通路的升级,高血压,运动能力受损,心脏功能障碍和纤维化增加.
- 多拉玛皮莫德治疗改善了血压,降低了心肌细胞缩和心肌纤维化,降低了心力衰竭生物标志物 (GAL-3,LDHA,BNP).
结论:
- 该MAPK信号通路与盐敏感性高血压诱导的HFpEF的发病有关.
- 在这个HFpEF模型中,多拉玛皮莫德在改善心脏功能障碍和病理变化方面表现出显著的治疗疗效.
- 抑制MAPK代表了管理与盐敏感高血压相关的HFpEF的潜在治疗策略.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:22Heart Failure Drugs: Diuretics
396
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
396
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: β-Blockers
342
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
342
01:07MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
01:26Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594